AU1599601A - Human igm antibodies to chemokine receptors - Google Patents

Human igm antibodies to chemokine receptors

Info

Publication number
AU1599601A
AU1599601A AU15996/01A AU1599601A AU1599601A AU 1599601 A AU1599601 A AU 1599601A AU 15996/01 A AU15996/01 A AU 15996/01A AU 1599601 A AU1599601 A AU 1599601A AU 1599601 A AU1599601 A AU 1599601A
Authority
AU
Australia
Prior art keywords
hiv
receptors
chemokine receptors
human igm
igm antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15996/01A
Other languages
English (en)
Inventor
Peter I. Lobo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MONICAID Corp
Original Assignee
MONICAID CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MONICAID CORP filed Critical MONICAID CORP
Publication of AU1599601A publication Critical patent/AU1599601A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
AU15996/01A 1999-11-14 2000-11-14 Human igm antibodies to chemokine receptors Abandoned AU1599601A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09439690 1999-11-14
US43969099A 1999-11-15 1999-11-15
US09684813 2000-10-10
US09/684,813 US6610834B1 (en) 1998-11-18 2000-10-10 Human IgM antibodies to chemokine receptors
PCT/US2000/031051 WO2001035980A1 (en) 1999-11-14 2000-11-14 HUMAN IgM ANTIBODIES TO CHEMOKINE RECEPTORS

Publications (1)

Publication Number Publication Date
AU1599601A true AU1599601A (en) 2001-05-30

Family

ID=27032133

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15996/01A Abandoned AU1599601A (en) 1999-11-14 2000-11-14 Human igm antibodies to chemokine receptors

Country Status (8)

Country Link
US (1) US6610834B1 (https=)
EP (1) EP1231930B1 (https=)
JP (1) JP2003516940A (https=)
AT (1) ATE464909T1 (https=)
AU (1) AU1599601A (https=)
CA (1) CA2389851A1 (https=)
DE (1) DE60044259D1 (https=)
WO (1) WO2001035980A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099645A1 (en) * 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
US20080118522A1 (en) * 1998-11-18 2008-05-22 Lobo Peter I Naturally occuring IgM antibodies that bind lymphocytes
MXPA06011824A (es) * 2004-04-16 2006-12-15 Genentech Inc Ensayo para anticuerpos.
CA2580801A1 (en) * 2004-12-01 2006-06-08 Peter I. Lobo Naturally occuring igm antibodies that bind lymphocytes
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
EP2397148A3 (en) 2006-02-02 2012-04-25 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007286451A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
KR20090052358A (ko) 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20210311048A1 (en) * 2016-02-16 2021-10-07 Celltrend Gmbh Anti-CXC chemokine receptor antibodies and C-X-C chemokines for the diagnosis of autoimmune disease and graft-versus-host disease
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US5606026A (en) * 1988-03-25 1997-02-25 The Institute For Human Genetics And Biochemistry Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
AU3505397A (en) * 1996-06-25 1998-01-14 Trustees Of The University Of Pennsylvania, The Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
JP2000229997A (ja) * 1999-02-10 2000-08-22 Nissui Pharm Co Ltd 環状ペプチド及びエイズワクチン

Also Published As

Publication number Publication date
EP1231930B1 (en) 2010-04-21
US6610834B1 (en) 2003-08-26
EP1231930A1 (en) 2002-08-21
ATE464909T1 (de) 2010-05-15
JP2003516940A (ja) 2003-05-20
WO2001035980A1 (en) 2001-05-25
DE60044259D1 (de) 2010-06-02
EP1231930A4 (en) 2005-07-27
CA2389851A1 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
AU1599601A (en) Human igm antibodies to chemokine receptors
Clerici et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41
Ditse et al. HIV-1 subtype C-infected children with exceptional neutralization breadth exhibit polyclonal responses targeting known epitopes
Liu et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
PT1159298E (pt) Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
Kohler et al. Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination
Michaud et al. Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection
Pereira et al. Simian immunodeficiency virus (SIV) infection influences the level and function of regulatory T cells in SIV-infected rhesus macaques but not SIV-infected sooty mangabeys
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
Lopalco et al. Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I α1 peptide‐binding domain
WO2002064615A3 (en) Monoclonal antibodies to human immunodeficiency virus and uses thereof
Klasse et al. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?
Losman et al. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region
Nabi et al. Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy
Kulkarni et al. Indian long-term non-progressors show broad ADCC responses with preferential recognition of V3 region of envelope and a region from Tat protein
Nelson et al. Simian-human immunodeficiency virus SHIV. CH505-infected infant and adult rhesus macaques exhibit similar env-specific antibody kinetics, despite distinct T-follicular helper and germinal center B cell landscapes
Greczmiel et al. LCMV‐specific CD4 T cell dependent polyclonal B‐cell activation upon persistent viral infection is short lived and extrafollicular
Hochleitner et al. Mass spectrometric characterization of a discontinuous epitope of the HIV envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A
Alsmadi et al. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities
Vieillard et al. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection
Hioe et al. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120
Lawoko et al. Increased immunoglobulin G, but not M, binding to endogenous retroviral antigens in HIV‐1 infected persons
Sattentau et al. New templates for HIV-1 antibody-based vaccine design
Koshino et al. Detection of Antibodies to HN-1 gp41-and HIA Class II Antigen-derived Peptides in SLE Patients
Skott et al. Salivary sIgA response in HIV-1 infection

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase